# Nilotinib in Huntington's Disease

> **NCT03764215** · PHASE1 · UNKNOWN · sponsor: **Georgetown University** · enrollment: 10 (estimated)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** Nilotinib 150 MG

## Key facts

- **NCT ID:** NCT03764215
- **Lead sponsor:** Georgetown University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-15
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03764215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03764215, "Nilotinib in Huntington's Disease". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT03764215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*